Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration – Aktuelle Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands e. V.

null Die redaktionellen Mitarbeiter sind am Ende des Beitrags gelistet.

doi:10.1055/s-0028-1109432

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000031.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Klin Monbl Augenheilkd 2009; 226(5): 388-395
DOI: 10.1055/s-0028-1109432

Statement

Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration – Aktuelle Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands e. V.

New Aspects in the Management of Exudative Age-Related Macular Degeneration – Current Position of the Retinological Society, the German Ophthalmology Society and the Professional Union of Ophthalmologists in Germany Die redaktionellen Mitarbeiter sind am Ende des Beitrags gelistet.

Further Information

Publication History

Eingegangen: 25.3.2009

Angenommen: 30.3.2009

Publication Date:
08 June 2009 (online)

Also available at

Abstract
Full Text
References

Permissions and Reprints

Abstract

The socioeconomic strategy and some scientific aspects in the management of exudative age related macular degeneration (AMD) have changed since the last publication on preferred practice pattern [1] [2]. Furthermore new drugs are tested in clinical trials. Consequently it seems reasonable to re-evaluate the redommendations for the treatment of exudative AMD.

Schlüsselwörter

altersbedingte Makuladegeneration - Behandlungsrichtlinien

Key words

age related macular degeneration - preferred practice pattern

Literatur

1 Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Moglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd. 2007; 224 559-566

Google Scholar
2 Aktuelle therapeutische Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Moglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe. 2007; 104 628-634

Google Scholar
3 Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Klin Monatsbl Augenheilkd. 2006; 223 271-278

Google Scholar
4 Antoszyk A N, Tuomi L, Chung C Y. et al . Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008; 145 862-874

Google Scholar
5 Schmidt-Erfurth U, Wolf S. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol. 2008; 92 1628-1635

Google Scholar
6 Singerman L J, Masonson H, Patel M. et al . Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008; 92 1606-1611

Google Scholar
7 Gragoudas E S, Adamis A P, Cunningham E T. et al . Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351 2805-2816

Google Scholar
8 Chakravarthy Jr U, Adamis A P, Cunningham E T. et al . Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006; 113 1508-1521

Google Scholar
9 Farah S E. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed. Ophthalmic Surg Lasers Imaging. 2008; 39 294-298

Google Scholar
10 Hughes M S, Sang D N. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2006; 37 446-454

Google Scholar
11 Brown D M, Kaiser P K, Michels Jr M. et al . Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355 1432-1444

Google Scholar
12 Rosenfeld P J, Brown D M, Heier J S. et al . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355 1419-1431

Google Scholar
13 Fachinformation Lucentis® (Stand August 2008). Rote Liste GmbH Novartis Pharma GmbH 2008

Google Scholar
14 Regillo C D, Brown D M, Abraham P. et al . Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008; 145 239-248

Google Scholar
15 Lommatzsch A P, Heimes B, Gutfleisch M. et al . Die Therapie der vaskularisierten serosen Pigmentepithelabhebung bei AMD – Beobachtungen nach Wechsel des intravitrealen Medikamentes bei Therapieversagen. Klin Monatsbl Augenheilkd. 2008; 225 874-879

Google Scholar
16 Alexander S L, Linde-Zwirble W T, Werther W. et al . Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology. 2007; 114 2174-2178

Google Scholar
17 Dafer R M, Schneck M, Friberg T R. et al . Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol. 2007; 22 201-204

Google Scholar
18 Investigator Notification for ranibizumab: Lucentis Meta-Analysis. Novartis NSO Basel CH 2008

Google Scholar
19 Rote-Hand-Brief: Avastin – Bevacizumab. Roche Pharma AG. 2009; , http://www.pei.de/SharedDocs/Downloads/fachkreise/rhb/ 09 – 02 – 11-rhb-avastin,templateId = raw,property = publicationFile.pdf/ 09 – 02 – 11-rhb-avastin.pdf

Google Scholar
20 Wild C, Adlbrecht C. Avastin® bei Altersbedingter Makuladegeneration. Analyse der Sicherheit und Nebenwirkungen. 2007; , http://eprints.hta.lbg.ac.at/ 718 / 1 /Rapid_Assessment_002.pdf

Google Scholar
21 Schouten J S, La Heij E C, Webers C A. et al . A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009; 247 1-11

Google Scholar
22 Ip M S, Scott I U, Brown G C. et al . Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008; 115 1837-1846

Google Scholar
23 Gamulescu M A, Framme C, Sachs H. RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol. 2007; 245 1037-1040

Google Scholar
24 Kook D, Wolf A, Neubauer A S. et al . Retinale Pigmentepithelrisse nach intravitrealem Bevacizumab bei AMD. Häufigkeit und Verlauf. Ophthalmologe. 2008; 105 158-164

Google Scholar
25 Weinberger A W, Thiel M, Mohammadi B. et al . Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol. 2007; 144 294-296

Google Scholar
26 Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). , http://www.med.upenn.edu/cpob/studies/CATT.shtml

Google Scholar
27 Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA). , http://www.clinicaltrials.gov/ct2 /show/NCT00559715

Google Scholar
28 Prävention des Sehverlustes bei Patienten mit altersabhängiger Makuladegeneration durch intravitreale Injektion von Bevacizumab und Ranibizumab. , http://www.pharmakologie-bremen.de/index.php/klinische-forschung/vibera

Google Scholar
29 A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation. , http://www.controlled-trials.com/ISRCTN92166560

Google Scholar
30 Fintak D R, Shah G K, Blinder K J. et al . Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008; 28 1395-1399

Google Scholar
31 Angulo Bocco M C, Glacet-Bernard A, Zourdani A. et al . Injection intravitréenne: évaluation rétrospective de la technique et des complications d’une serie de 2028 injections. J Fr Ophtalmol. 2008; 31 693-698

Google Scholar
32 Wu L, Martinez-Castellanos M A, Quiroz-Mercado H. et al . Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008; 246 81-87

Google Scholar
33 Chappelow A V, Kaiser P K. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008; 68 1029-1036

Google Scholar
34 Nguyen Q D, Shah S M, Hafiz G. et al . A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006; 113 1522 e1521-1522 e1514

Google Scholar
35 VEGF Trap-Eye in Wet AMD CLEAR-IT 2: Summary of One-Year Key Results. 2008; , http://library.corporate-ir.net/library/ 11 / 119 / 119 576 /items/ 309 061 /Final2_0508_Week52_Website_Slides_9 – 26 – 08.pdf

Google Scholar
36 Kleinman M E, Yamada K, Takeda A. et al . Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452 591-597

Google Scholar
37 Dejneka N S, Wan S, Bond O S. et al . Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis. 2008; 14 997-1005

Google Scholar
38 OPKO Health Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD. 2008; http://investor.opko.com/releasedetail.cfm?ReleaseID=352313

Google Scholar
39 Heimes B, Lommatzsch A, Zeimer M. et al . Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol. 2008; 246 1229-1234

Google Scholar
40 Macular Photocoagulation Study Group . Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 1991; 109 1109-1114

Google Scholar
41 Colquitt J L, Jones J, Tan S C. et al . Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2008; 12 iii-iv, ix-201

Google Scholar
42 NICE technology appraisal guidance 155. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. 2008; , www.nice.org.uk/TA155

Google Scholar
43 Schmidt-Erfurth U M, Richard G, Augustin A. et al . Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007; 85 486-494

Google Scholar
44 Empfehlung der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands für die Durchführung von intravitrealen Injektionen (IVI). 2007; , http://www.dog.org/publikationen/DOG_Empfehlung_Intravitreale_Injektionen.pdf

Google Scholar
45 Aiello L P, Brucker A J, Chang S. et al . Evolving guidelines for intravitreous injections. Retina. 2004; 24 S3-19

Google Scholar
46 Scott I U, Flynn H W. Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007; 27 10-12

Google Scholar
47 Meyer C H, Mennel Jr S, Eter N. Endophthalmitisrate mit und ohne topische postoperative Antibiotikagabe nach intravitrealer Avastin-injektion. Ophthalmologe. 2007; 104 952-957

Google Scholar
48 Hart D. Off-Label-Use von Arzneimitteln: Hintergründe und Lösungsansätze eines vielschichtigen Problems. Arzneimittelbrief. 2008; 42 81-96

Google Scholar
49 Dierks C, Nitz G. Rechtsfortbildung dank Lucentis?. Gesellschaftspolitische Kommentare. 2008; 11 3-7

Google Scholar
50 Hart D. Arzthaftung und off label use. Information, Standard und Zulassung. Medizinrecht heute: Erfahrungen, Analysen, Entwicklungen Festschrift: 10 Jahre Arbeitsgemeinschaft Medizinrecht im DAW Deutscher Anwaltverlag 2008: 173-190

Google Scholar
51 Francke R, Hart D. Off label use – Arzneimittelrechtliche, haftungsrechtliche, berufsrechtliche und sozialrechtliche Fragen. Die Sozialgerichtsbarkeit. 2003; 50 653-664

Google Scholar

>